Lucio Boglione1, Jessica Cusato2, Giuseppe Cariti2, Giovanni Di Perri2, Antonio D'Avolio3. 1. Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, Turin, Italy. Electronic address: lucio.boglione@gmail.com. 2. Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, Turin, Italy. 3. Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, Turin, Italy. Electronic address: antonio.davolio@unito.it.
Abstract
OBJECTIVES: 10 hepatitis B virus (HBV) genotypes are known with different geographic distribution and response to interferon (IFN) therapy. The E genotype is the more prevalent genotype in West and Central Africa, but few data about response to IFN are available. We describe the epidemiological and clinical characteristics in a cohort of patients immigrants from Africa in our country with HBV E genotype chronic hepatitis infection (CHB). METHODS: 63 patients with CHB and E genotype were included; 41 with CHB and low viral load were treated with PEG-IFN monotherapy; 10 with CHB and high viral load with sequential approach (entecavir and PEG-IFN). 12 patients with inactive CHB were followed with blood sample and abdomen ultrasonography every six months. RESULTS: The virological response in the monotherapy group was 17.9%. Hepatitis B surface antigen (HBsAg) loss was observed in 1 patient (2.5%); 56 patients (88%) showed at the time of diagnosis of CHB another infectious diseases that required specific treatment before PEG-IFN; this treatment was also affected by an higher incidence of side-effects (>50%). All patients with high viremia showed a primary non-response to PEG-IFN. CONCLUSIONS: The HBV E genotype evidences the worse response to PEG-IFN and maybe requires novel treatment options.
OBJECTIVES: 10 hepatitis B virus (HBV) genotypes are known with different geographic distribution and response to interferon (IFN) therapy. The E genotype is the more prevalent genotype in West and Central Africa, but few data about response to IFN are available. We describe the epidemiological and clinical characteristics in a cohort of patients immigrants from Africa in our country with HBV E genotype chronic hepatitis infection (CHB). METHODS: 63 patients with CHB and E genotype were included; 41 with CHB and low viral load were treated with PEG-IFN monotherapy; 10 with CHB and high viral load with sequential approach (entecavir and PEG-IFN). 12 patients with inactive CHB were followed with blood sample and abdomen ultrasonography every six months. RESULTS: The virological response in the monotherapy group was 17.9%. Hepatitis B surface antigen (HBsAg) loss was observed in 1 patient (2.5%); 56 patients (88%) showed at the time of diagnosis of CHB another infectious diseases that required specific treatment before PEG-IFN; this treatment was also affected by an higher incidence of side-effects (>50%). All patients with high viremia showed a primary non-response to PEG-IFN. CONCLUSIONS: The HBV E genotype evidences the worse response to PEG-IFN and maybe requires novel treatment options.
Authors: Lucio Boglione; Ilaria De Benedetto; Tommaso Lupia; Jessica Cusato; Giuseppe Cariti; Giovanni Di Perri Journal: Arch Virol Date: 2021-02-12 Impact factor: 2.574
Authors: Sylvia Drazilova; Martin Janicko; Pavol Kristian; Ivan Schreter; Branislav Kucinsky; Marek Kozlej; Ivana Hockickova; Peter Jarcuska Journal: Gastroenterol Res Pract Date: 2015-12-29 Impact factor: 2.260
Authors: Noé Escobar-Escamilla; David Esaú Fragoso-Fonseca; Dulce María Arreguín-Porras; María Del Carmen Esteban-Valencia; Estela Corona-Valdespino; Jaime Israel Falcón-Acosta; Roberto Vázquez-Campuzano; Fabiola Garcés-Ayala; Joanna María Ortiz-Alcantara; Irma López-Martinez; José Alberto Diaz-Quiñonez; José Ernesto Ramírez-González Journal: Genome Announc Date: 2016-03-31